Citations

Clear

861 citation(s) found for "Sd, Wexner".

The Aging Surgeon: Evidence and Experience
Asserson, Derek B. , Janis, Jeffrey E.

Mayo Clinic

Aesthetic Surgery Journal | March 23, 2021 | Volume: 42 | Issue: 1 | Pages: 121-127

10.1093/asj/sjab145 | PMID 33755726 Get It

Abstract Background With doctors in short supply and a strong demand for surgeon services in all areas of the United States, urban and rural, there are pressures to remain in active practice for longer. Even with an older workforce, there are currently no requirements for when a surgeon must retire in the United States. Objectives The aim of this article was to highlight the importance of the aging surgeon to the medical community and to provide an evidence-based overview of age-related cognitive and physical issues that develop during the later stages of a surgeon’s career. Methods A search of the PubMed/MEDLINE database was performed for the phrase “aging surgeon.” Inclusion criteria were applied to include only those articles related to surgeon age or retirement. Additional reports were handpicked from citations to substantiate claims with statistical evidence. Results The aging surgeon contributes extensive experience to patient care, but is also prone to age-related changes in cognition, vision, movement, and stress as it relates to new techniques, surgical performance, and safety measures. Studies show that although surgeons are capable of operating well into their senior years, there is the potential of decline. Nevertheless, there are proven recommendations on how to prepare an older surgeon for retirement. Conclusions Age-related trends in cognitive and physical decline must be counterbalanced with wisdom gained through decades of surgical experience.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
Rogers, Kerry A. , Andritsos, Leslie A. , Wei, Lai , McLaughlin, Eric , Ruppert, Amy S. , Anghelina, Mirela , Blachly, James S. , Call, Timothy G. , Chihara, Dai , Dauki, Anees M. , James, Lacey, Kreitman, Robert J. , Lozanski, Gerard , Lucas, David , Ngankeu, Apollinaire, Phelps, Mitch A. , Schiffer, Charles A. , Carson, William E. , Jones, Jeffrey A. , Grever, Michael R. , Call, Timothy, Dauki, Anees , Carson, William E , Wei, Lai , Chihara, Dai , Blachly, James , Phelps, Mitch , Guo, Ling Jun , Ivy, S. Percy , Jones, Daniel R. , Ravandi, Farhad

Mayo Clinic

Blood | March 23, 2021 | Volume: 137 | Issue: 25 | Pages: 3473-3483

10.1182/blood.2020009688 | PMID 33754642 Get It

Abstract Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its activity in HCL was unknown, so we conducted a multisite phase 2 study of oral ibrutinib in patients with either relapsed classic or variant hairy cell leukemia. The primary outcome measure was the overall response rate (ORR) at 32 weeks, and we also assessed response at 48 weeks and best response during treatment. Key secondary objectives were characterization of toxicity and determination of progression-free survival (PFS) and overall survival (OS). Thirty-seven patients were enrolled at 2 different doses (24 at 420 mg, 13 at 840 mg). The median duration of follow-up was 3.5 years (range, 0-5.9 years). The ORR at 32 weeks was 24%, which increased to 36% at 48 weeks. The best ORR was 54%. The estimated 36-month PFS was 73% and OS was 85%. The most frequent adverse events were diarrhea (59%), fatigue (54%), myalgia (54%), and nausea (51%). Hematologic adverse events were common: anemia (43%), thrombocytopenia (41%), and neutropenia (35%). Ibrutinib can be safely administered to patients with HCL with objective responses and results in prolonged disease control. Although the initial primary outcome objective of the study was not met, the observation of objective responses in heavily pretreated patients coupled with a favorable PFS suggests that ibrutinib may be beneficial in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01841723.
Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial
Gertz, Zachary M. , Herrmann, Howard C. , Lim, D. Scott , Kapadia, Samir , Reed, Grant W. , Puri, Rishi , Krishnaswamy, Amar , Gersh, Bernard J. , Weissman, Neil J., Grayburn, Paul , Redfors, Björn , Zhang, Zixuan , Abraham, William T. , Stone, Gregg W. , Mack, Michael J. , Kapadia, Samir , Herrmann, Howard C , Gersh, Bernard J , Reed, Grant W , Lim, D Scott , Kar, Saibal , Asch, Federico M. , Kosmidou, Ioanna , Lindenfeld, JoAnn

Mayo Clinic

Circulation: Cardiovascular Interventions | March 15, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.010300 | PMID 33719505 Get It

Background: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. Methods: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. Results: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P =0.01) and adjusted (HR, 1.30 [1.03–1.64], P =0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF ( P int =0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; P int =0.02). Conclusions: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
Use of magnetic resonance imaging lymphangiography for preoperative planning in lymphedema surgery: A systematic review
Forte, Antonio J. , Huayllani, María T. , Guliyeva, Günel , Lu, Xiaona , Mash, William R., Kung, Theodore A. , Boczar, Daniel , Huayllani, Maria T , Ávila, Francisco R. , Forte, Antonio Jorge

Mayo Clinic

Microsurgery | March 12, 2021 | Volume: 41 | Issue: 4 | Pages: 384-390

10.1002/micr.30731 | PMID 33710683 Get It

AbstractBackgroundIn recent years, magnetic resonance imaging lymphangiography (MRL) has emerged as a way to predict if patients are candidates for lymphedema surgery, particularly lymphovenous anastomosis (LVA). Our goal was to conduct a systematic review of the literature on the use of MRL for preoperative planning in lymphedema surgery. We hypothesized that MRL could add valuable information to the standard preoperative evaluation of lymphedema patients.MethodsOn February 17, 2020, we conducted a systematic review of the PubMed/MEDLINE, Cochrane Clinical Answers, and Embase databases, without time frame or language limitations, to identify articles on the use of MRL for preoperative planning of lymphedema surgery. We excluded studies that investigated other applications of magnetic resonance imaging, such as lymphedema diagnosis and treatment evaluation. The primary outcome was the examination capacity to identify lymphatic anatomy and the secondary outcome was the presence of adverse effects.ResultsOf 372 potential articles identified with the search, nine studies fulfilled the eligibility criteria. A total of 334 lymphedema patients were enrolled in these studies. Two studies compared MRL findings with those of other standard examinations (indocyanine green lymphography [ICG‐L] or lymphoscintigraphy). No adverse effects due to MRL were reported. A study shown that MRL had higher sensitivity to detect lymphatic vessel abnormalities compared with lymphoscintigraphy and a statistically higher chance of successful LVA was observed when the results of MRL agreed with those of ICG‐L (p < .001).ConclusionsMRL could be useful for preoperative planning in lymphedema surgery. The scientific evidence has been limited, so further studies with greater numbers of patients and cost analysis are necessary to justify the addition of MRL to current preoperative protocols.
Guidelines for Perioperative Care for Emergency Laparotomy Enhanced Recovery After Surgery (ERAS) Society Recommendations: Part 1—Preoperative: Diagnosis, Rapid Assessment and Optimization
Peden, Carol J. , Aggarwal, Geeta , Aitken, Robert , Anderson, I D , Cooper, Zara , Dhesi, Jugdeep , French, W. Brenton, Hammarqvist, Folke , Hare, Sarah P., Havens, Joaquim M. , Holena, Daniel N. , Hübner, Martin , Kim, Jeniffer S. , Lees, Nicholas P. , Ljungqvist, Olle , Lobo, Dileep N. , Quiney, Nial , Wick, Elizabeth C. , Young‐Fadok, Tonia M., Scott, Michael J. , Cooper, Zara , Aitken, Robert J , Cooper, Zara , Lees, Nicholas P , Lobo, D N , Mohseni, Shahin , Ordoñez, Carlos A , Urman, Richard D , Young-Fadok, Tonia, Scott, M J , Peden, Carol J , Hübner, Martin , Foss, Nicolai Bang , Grant, Michael Conrad , Mohseni, Shahin , Ordóñez, Carlos A. , Wu, Christopher L

Mayo Clinic

World Journal of Surgery | March 6, 2021 | Volume: 45 | Issue: 5 | Pages: 1272-1290

10.1007/s00268-021-05994-9 | PMID 33677649 Get It

Abstract Background Enhanced Recovery After Surgery (ERAS) protocols reduce length of stay, complications and costs for a large number of elective surgical procedures. A similar, structured approach appears to improve outcomes, including mortality, for patients undergoing high‐risk emergency general surgery, and specifically emergency laparotomy. These are the first consensus guidelines for optimal care of these patients using an ERAS approach. Methods Experts in aspects of management of the high‐risk and emergency general surgical patient were invited to contribute by the International ERAS® Society. Pubmed, Cochrane, Embase, and MEDLINE database searches on English language publications were performed for ERAS elements and relevant specific topics. Studies on each item were selected with particular attention to randomized controlled trials, systematic reviews, meta‐analyses and large cohort studies, and reviewed and graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Recommendations were made on the best level of evidence, or extrapolation from studies on non‐emergency patients when appropriate. The Delphi method was used to validate final recommendations. The guideline has been divided into two parts: Part 1—Preoperative Care and Part 2—Intraoperative and Postoperative management. This paper provides guidelines for Part 1. Results Twelve components of preoperative care were considered. Consensus was reached after three rounds. Conclusions These guidelines are based on the best available evidence for an ERAS approach to patients undergoing emergency laparotomy. Initial management is particularly important for patients with sepsis and physiological derangement. These guidelines should be used to improve outcomes for these high‐risk patients.
Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis
Lee, Jaclyn , Huang, Li‐Ching , Berry, Lynn D., Anderson, Catherine , Amin, Milan R. , Benninger, Michael S. , Blumin, Joel H. , Bock, Jonathan M. , Bryson, Paul C. , Castellanos, Paul F., Chen, Sheau‐Chiann , Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fink, Daniel S. , Franco, Ramon A. , Garrett, C. Gaelyn , Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Hussain, Lena K., Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Lowery, Anne S. , Makani, Samir, Maldonado, Fabien , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , O’Dell, Karla , Ongkasuwan, Julina , Postma, Gregory N. , Reder, Lindsay , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Daele, Douglas J. Van , Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Cohen, Seth M , Dailey, Seth H , Hoffman, Henry T , Lott, David G , Mori, Matthew , Ongkasuwan, Julian , Richardson, Brent E , Gelbard, Alexander , Chen, Sheau-Chiann , Weissbrod, Philip A , Clary, Matthew S. , Guardiani, Elizabeth , Hillel, Alexander T. , Lott, David G. , Mannion, Kyle , Netterville, James L. , Rohde, Sarah L. , Weinberger, Paul , Gelbard, Alexander , Amin, Milan R

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 25, 2021 | Volume: 130 | Issue: 10 | Pages: 1116-1124

10.1177/0003489421995283 | PMID 33629608 Get It

Objectives: To examine whether social determinants of health (SDH) factors are associated with time to diagnosis, treatment selection, and time to recurrent surgical intervention in idiopathic subglottic stenosis (iSGS) patients. Methods: Adult patients with diagnosed iSGS were recruited prospectively (2015-2017) via clinical providers as part of the North American Airway Collaborative (NoAAC) and via an online iSGS support community on Facebook. Patient-specific SDH factors included highest educational attainment (self-reported), median household income (matched from home zip code via U.S. Census data), and number of close friends (self-reported) as a measure of social support. Main outcomes of interest were time to disease diagnosis (years from symptom onset), treatment selection (endoscopic dilation [ED] vs cricotracheal resection [CTR] vs endoscopic resection with adjuvant medical therapy [ERMT]), and time to recurrent surgical intervention (number of days from initial surgical procedure) as a surrogate for disease recurrence. Results: The total 810 participants were 98.5% female, 97.2% Caucasian, and had a median age of 50 years (IQR, 43-58). The cohort had a median household income of $62 307 (IQR, $50 345-$79 773), a median of 7 close friends (IQR, 4-10), and 64.7% of patients completed college or graduate school. Education, income, and number of friends were not associated with time to diagnosis via multivariable linear regression modeling. Univariable multinominal logistic regression demonstrated an association between education and income for selecting ED versus ERMT, but no associations were noted for CTR. No associations were noted for time to recurrent surgical procedure via Kaplan Meier modeling and Cox proportional hazards regression. Conclusions: Patient education, income, and social support were not associated with time to diagnosis or time to disease recurrence. This suggests additional patient, procedure, or disease-specific factors contribute to the observed variations in iSGS surgical outcomes.
Post–Acute Pancreatitis Pancreatic Exocrine Insufficiency
Machicado, Jorge D. , Lahooti, Ali , Kamal, Ayesha , Pothoulakis, Ioannis , REYNOLDS, SHARI L., Mays, Melanie, Conwell, Darwin L. , Lara, Luis F. , Paragomi, Pedram , Phillips, Anna Evans , Afghani, Elham , Singh, Vikesh K. , Papachristou, Georgios I.

Mayo Clinic

Pancreas | February 22, 2021 | Volume: 50 | Issue: 2 | Pages: 147-152

10.1097/mpa.0000000000001743 | PMID 33565790 Get It

Objectives We describe the methodology of Post–Acute Pancreatitis Pancreatic Exocrine Insufficiency (PAPPEI), a prospective, observational, multicenter cohort study. The objectives of PAPPEI are to estimate the incidence rate of post–acute pancreatitis (AP) pancreatic exocrine insufficiency (PEI), define factors that determine the development of post-AP PEI, and evaluate the impact of post-AP PEI on nutritional status and quality of life. Methods Enrollment started in June 2017 in 3 expert academic centers in the United States. Data were collected during hospitalization (baseline) at 3 and 12 months after enrollment. Fecal elastase-1 was used to assess PEI. Study questionnaires are completed by patient interview and review of electronic medical records. Blood is obtained to evaluate vitamin deficiencies and nutritional markers. Results As of August 2020, 77 subjects have completed the baseline evaluation. The median age was 58 years (interquartile range, 39–67 years), 38% were male, and 90% were white. The etiology of AP was biliary in 39 subjects (51%), and 51 subjects (66%) had mild AP. Three- and 12-month follow-up data have been collected in 29 and 13 subjects, respectively. Conclusion The PAPPEI study aims to expand our understanding of post-AP PEI incidence, including its impact on nutritional status and quality of life.
Dynamic changes in the pancreatitis activity scoring system during hospital course in a multicenter, prospective cohort
Paragomi, Pedram , Tuft, Marie , Pothoulakis, Ioannis , Stevens, Tyler , Nawaz, Haq , Easler, Jeffrey J. , Thakkar, Shyam , Coté, Gregory A. , Lee, Peter J. , Kamal, Ayesha , Gougol, Amir , Machicado, Jorge D. , Greer, Phil J. , Buxbaum, James , Hart, Phil A. , Conwell, Darwin L. , Tang, Gong , Akshintala, Venkata , Singh, Vikesh K. , Akshintala, Venkata S. , Phillips, Anna Evans , Whitcomb, David C. , Wu, Bechien U. , Papachristou, Georgios I.

Mayo Clinic

Journal of Gastroenterology and Hepatology | February 20, 2021 | Volume: 36 | Issue: 9 | Pages: 2416-2423

10.1111/jgh.15430 | PMID 33604947 Get It

AbstractBackground and AimThe primary aim was to validate the Pancreatitis Activity Scoring System (PASS) in a multicenter prospectively ascertained acute pancreatitis (AP) cohort. Second, we investigated the association of early PASS trajectories with disease severity and length of hospital stay (LOS).MethodsData were prospectively collected through the APPRENTICE consortium (2015–2018). AP severity was categorized based on revised Atlanta classification. Delta PASS (ΔPASS) was calculated by subtracting activity score from baseline value. PASS trajectories were compared between severity subsets. Subsequently, the cohort was subdivided into three LOS subgroups as short (S‐LOS): 2–3 days; intermediate (I‐LOS): 3–7 days; and long (L‐LOS): ≥7 days. The generalized estimating equations model was implemented to compare PASS trajectories.ResultsThere were 434 subjects analyzed including 322 (74%) mild, 86 (20%) moderately severe, and 26 (6%) severe AP. Severe AP subjects had the highest activity levels and the slowest rate of decline in activity (P = 0.039). Focusing on mild AP, L‐LOS subjects (34%) had 28 points per day slower decline; whereas, S‐LOS group (13%) showed 34 points per day sharper decrease compared with I‐LOS (53%; P < 0.001). We noticed an outlier subset with a median admission‐PASS of 466 compared with 140 in the rest. Morphine equivalent dose constituted 80% of the total PASS in the outliers (median morphine equivalent dose score = 392), compared with only 25% in normal‐range subjects (score = 33, P value < 0.001).ConclusionsThis study highlighted that PASS can quantify AP activity. Significant differences in PASS trajectories were found both in revised Atlanta classification severity and LOS groups, which can be harnessed in AP monitoring/management (ClincialTrials.gov number, NCT03075618).